PMID- 35243515
OWN - NLM
STAT- MEDLINE
DCOM- 20230320
LR  - 20230320
IS  - 1615-6692 (Electronic)
IS  - 0340-9937 (Linking)
VI  - 48
IP  - 2
DP  - 2023 Mar
TI  - Current status of antithrombotic therapy and in-hospital outcomes in patients 
      with atrial fibrillation undergoing percutaneous coronary intervention in 
      Germany.
PG  - 134-140
LID - 10.1007/s00059-022-05099-6 [doi]
AB  - BACKGROUND: Little is known about current patterns of antithrombotic therapy in 
      patients with atrial fibrillation (AF) undergoing percutaneous coronary 
      intervention (PCI) in clinical practice in Germany. METHODS: The RIVA-PCI is 
      a prospective, non-interventional, multicenter study with follow-up until 
      hospital discharge including consecutive patients with AF undergoing PCI. 
      RESULTS: Between January 2018 and March 2020, 1636 patients (elective in 52.6%, 
      non-ST elevation acute coronary syndrome [NSTE-ACS] in 39.3%, ST-elevation 
      myocardial infarction in 8.2%) from 51 German hospitals were enrolled in the 
      study. After PCI a dual antithrombotic therapy (DAT) consisting of OAC and 
      a P2Y12 inhibitor was given to 66.0%, triple antithrombotic therapy (TAT) to 
      26.0%, dual antiplatelet therapy to 5.5%, and a mono-therapy to 2.5% of the 
      patients. Non-vitamin K antagonist oral anticoagulants (NOACs) were given to 
      82.4% and vitamin K antagonists to 11.5% of the patients. In-hospital events 
      included death in 12 cases (0.7%), myocardial infarction, stent thrombosis, and 
      ischemic stroke in four (0.2%) patients each, while 2.8% of patients had bleeding 
      complications. The recommended durations for DAT or TAT at discharge were 1 month 
      (1.5%), 3 months (2.1%), 6 months (43.1%), and 12 months (45.6%), with a 6-month 
      course of DAT (47.7%) most often recommended after elective PCI and a 12-month 
      course of DAT (40.1%) after ACS. CONCLUSION: The preferred therapy after PCI in 
      patients with AF is DAT with a NOAC and clopidogrel. In-hospital ischemic and 
      bleeding events were rare. The recommended durations for combination therapy vary 
      considerably.
CI  - (c) 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, 
      ein Teil von Springer Nature.
FAU - Zeymer, Uwe
AU  - Zeymer U
AD  - Medizinische Klinik B, Klinikum Ludwigshafen, Bremserstrasse 79, 67063, 
      Ludwigshafen, Germany. Uwe.Zeymer@t-online.de.
AD  - Institut fur Herzinfarktforschung Ludwigshafen, Ludwigshafen, Germany. 
      Uwe.Zeymer@t-online.de.
FAU - Toelg, Ralph
AU  - Toelg R
AD  - Segeberger Kliniken GmbH, Bad Segeberg, Germany.
FAU - Wienbergen, Harm
AU  - Wienbergen H
AD  - Klinikum Links der Weser Bremen, Bremen, Germany.
FAU - Hobbach, Hans-Peter
AU  - Hobbach HP
AD  - Kreisklinikum Siegen, Siegen, Germany.
FAU - Cuneo, Alessandro
AU  - Cuneo A
AD  - Krankenhaus und MVZ Maria-Hilf Stadtlohn, Stadtlohn, Germany.
FAU - Bekeredjian, Raffi
AU  - Bekeredjian R
AD  - Robert-Bosch-Klinikum, Stuttgart, Germany.
FAU - Ritter, Oliver
AU  - Ritter O
AD  - Klinikum Brandenburg Havel, Brandenburg, Germany.
FAU - Hailer, Birgit
AU  - Hailer B
AD  - Katholische Kliniken Essen-Nord-West gGmbH, Essen, Germany.
FAU - Hertting, Klaus
AU  - Hertting K
AD  - Krankenhaus Buchholz und Winsen GmbH, Buchholz, Germany.
FAU - Hennersdorf, Marcus
AU  - Hennersdorf M
AD  - SLK-Kliniken Heilbronn GmbH, Heilbronn, Germany.
FAU - Scholtz, Werner
AU  - Scholtz W
AD  - Herz- und Diabeteszentrum, Bad Oeynhausen, Germany.
FAU - Lanzer, Peter
AU  - Lanzer P
AD  - Gesundheitszentrum Bitterfeld Wolfen, Bitterfeld, Germany.
FAU - Mudra, Harald
AU  - Mudra H
AD  - Stadtisches Krankenhaus Neuperlach-Munchen, Munchen, Germany.
FAU - Schwefer, Markus
AU  - Schwefer M
AD  - Elblandklinikum Riesa, Riesa, Germany.
FAU - Schwimmbeck, Peter-Lothar
AU  - Schwimmbeck PL
AD  - Klinikum Leverkusen, Leverkusen, Germany.
FAU - Liebetrau, Christoph
AU  - Liebetrau C
AD  - Kerckhoff-Klinik GmbH, Bad Nauheim, Germany.
FAU - Thiele, Holger
AU  - Thiele H
AD  - Herzzentrum Leipzig und Universitat Leipzig, Leipzig, Germany.
FAU - Claas, Christoph
AU  - Claas C
AD  - Institut fur Herzinfarktforschung Ludwigshafen, Ludwigshafen, Germany.
FAU - Riemer, Thomas
AU  - Riemer T
AD  - Institut fur Herzinfarktforschung Ludwigshafen, Ludwigshafen, Germany.
FAU - Zahn, Ralf
AU  - Zahn R
AD  - Medizinische Klinik B, Klinikum Ludwigshafen, Bremserstrasse 79, 67063, 
      Ludwigshafen, Germany.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
TT  - Aktueller Stand der antithrombotischen Therapie und stationare Ergebnisse bei 
      Patienten mit Vorhofflimmern nach perkutaner Koronarintervention in Deutschland.
DEP - 20220303
PL  - Germany
TA  - Herz
JT  - Herz
JID - 7801231
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Fibrinolytic Agents)
SB  - IM
MH  - Humans
MH  - Anticoagulants/therapeutic use
MH  - *Atrial Fibrillation/complications/drug therapy
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Fibrinolytic Agents/therapeutic use
MH  - *Percutaneous Coronary Intervention
MH  - Prospective Studies
MH  - Administration, Oral
MH  - Drug Therapy, Combination
MH  - Hospitals
OTO - NOTNLM
OT  - Antithrombotic therapy
OT  - Atrial fibrillation
OT  - Oral anticoagulation
OT  - Percutaneous coronary intervention
OT  - Registry
EDAT- 2022/03/05 06:00
MHDA- 2023/03/21 06:00
CRDT- 2022/03/04 05:45
PHST- 2021/08/28 00:00 [received]
PHST- 2022/01/24 00:00 [accepted]
PHST- 2021/12/06 00:00 [revised]
PHST- 2022/03/05 06:00 [pubmed]
PHST- 2023/03/21 06:00 [medline]
PHST- 2022/03/04 05:45 [entrez]
AID - 10.1007/s00059-022-05099-6 [pii]
AID - 10.1007/s00059-022-05099-6 [doi]
PST - ppublish
SO  - Herz. 2023 Mar;48(2):134-140. doi: 10.1007/s00059-022-05099-6. Epub 2022 Mar 3.